document: Next, we investigated the distribution of the Qβ VLPs-based therapeutics in tumour tissue after CED infusion (Figure 6a and 6b). Both rQβ@b-3WJsiEGFR Let-7g and TrQβ@b-3WJsiEGFR Let-7g can penetrate into the tumour tissue from the injection site located at the junction of tumour tissue and normal brain tissue after 0.5 h of CED infusion, and reached the maximum dose at 2 h. Moreover, increasingly stronger red fluorescence signals were observed for TrQβ@b-3WJsiEGFR Let-7g and significantly